Get the Stockscreener App
38.95
1.46%
0.51
Ionis Pharmaceuticals Inc stock is traded at $38.95, with a volume of 482.59K.
It is up +1.46% in the last 24 hours and up +2.88% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$38.44
Open:
$38.01
24h Volume:
482.59K
Relative Volume:
0.32
Market Cap:
$6.08B
Revenue:
$813.46M
Net Income/Loss:
$-365.74M
P/E Ratio:
-13.57
EPS:
-2.87
Net Cash Flow:
$-375.18M
1W Performance:
-1.79%
1M Performance:
+2.88%
6M Performance:
-7.08%
1Y Performance:
-17.36%
1-Day Range:
$37.53
$39.07
1-Week Range:
$37.53
$40.12
52-Week Range:
$35.95
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com - MarketBeat
FDA Sets Goal Date for Donidalorsen in HAE - Managed Healthcare Executive
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
FDA accepts donidalorsen NDA for prophylactic hereditary angioedema - Contemporary Pediatrics
FDA accepts Ionis NDA for donidalorsen - The Pharma Letter
Ionis' donidalorsen awaits FDA decision for HAE treatment - Investing.com
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PR Newswire
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Shareholders in Ionis Pharmaceuticals (NASDAQ:IONS) have lost 32%, as stock drops 4.0% this past week - Simply Wall St
abrdn plc Has $12.06 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Zilganersen granted U.S. FDA Fast Track designation for people l - GuruFocus.com
Ionis to hold third quarter 2024 financial results webcast - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 6.3% in October - MarketBeat
International Assets Investment Management LLC Buys 319,065 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Wednesday - MarketBeat
Antisense Oligonucleotides Market Is Booming Worldwide - openPR
HEART FAILURE (HF) WITH REDUCED EJECTION FRACTION (HFREF) - openPR
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B - BioPharma Dive
Multiple System Atrophy Market Growth to Accelerate in Forecast - openPR
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Lowered to Sell at StockNews.com - MarketBeat
Ionis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory Successes (NASDAQ:IONS) - Seeking Alpha
Analysts Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.28 - MarketBeat
Certain warrants of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024. - Marketscreener.com
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling - Seeking Alpha
Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years - Yahoo Finance
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN - Yahoo! Voices
AZ, Ionis get CHMP backing for ATTR polyneuropathy drug - pharmaphorum
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
Ionis Pharmaceuticals EVP Eric Swayze sells $2,030 in stock - Investing.com
Ionis Pharmaceuticals EVP Eric Swayze sells $2,030 in stock By Investing.com - Investing.com UK
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Spinal Muscular Atrophy Pipeline Insights 2024: Therapies, - openPR
Q3 2024 Earnings Forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Issued By Leerink Partnrs - MarketBeat
Ionis Pharmaceuticals Enters Oversold Territory (IONS) - Nasdaq
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Acromegaly Pipeline Insights and Analysis 2024: FDA Approvals , and Treatment Outlook | Pfizer Inc, Novartis AG, Validus Pharma, Ipsen, Chiasma, Inc, Crinetics Pharma, Ionis Pharma - Barchart
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Global Antisense & RNAi Therapeutics Market Growth in Future - openPR
Familial Chylomicronemia Syndrome Therapeutics Market to Expand with Significant CAGR by 2034 |Akcea Therapeutics, Ionis – IndiaPolitics.com - IndiaPolitics.com
Sanctuary Advisors LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Where are the Opportunities in (IONS) - Stock Traders Daily
Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - The Pantagraph
Millennium Management LLC Has $6.11 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
Dimensional Fund Advisors LP Has $4.23 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds - Insider Monkey
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swayze Eric | EVP Research |
Oct 16 '24 |
Sale |
38.31 |
53 |
2,031 |
157 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 29 '24 |
Sale |
49.63 |
331 |
16,428 |
84,823 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 28 '24 |
Sale |
49.16 |
320 |
15,731 |
85,154 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 05 '24 |
Sale |
48.00 |
2,430 |
116,640 |
85,508 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):